How did patients with VEXAS syndrome respond to various treatments in the study?
VEXAS syndrome is a rare condition caused by a mutation in the UBA1 gene that leads to inflammation and blood problems. Patients typically face a difficult choice between treatments that work fast but cause long-term issues versus those that take longer to work but may be more sustainable. Research shows that corticosteroids provide rapid early improvement, but patients often face dependence and difficulty tapering the medication 1. In contrast, hypomethylating agents (HMA) show a gradual and sustained increase in global, clinical, and biological responses over time 1.
What the research says
Studies involving 40 male patients found that overall, 58 different treatment lines were administered, including corticosteroids, JAK inhibitors, anti-IL1 and anti-IL6 agents, and hypomethylating agents 1. While corticosteroids led to rapid early improvement, their use was limited by dependence and tapering difficulties 1. Hypomethylating agents reached high proportions of improvement at 12 months, even though they were used predominantly in more refractory patients 1.
A separate study of 88 patients found that azacitidine, a type of hypomethylating agent, showed potential but data remain limited 6. Inflammatory response rates were 41% at 6 months and 54% at 12 months, regardless of MDS status 6. This suggests a delayed median response for these drugs 6. Among responders, relapse-free survival on azacitidine was 90% at 1 year and 85% at 5 years 6. Hematological responses included red blood cell transfusion independence in 65% and platelet improvement in 77% of patients 6.
Another study of 16 Chinese patients noted that corticosteroids and immunosuppressants commonly provided symptomatic relief, while variable hematologic responses were observed 3. This aligns with the broader finding that while steroids work quickly, other agents are needed for sustained control 3.
What to ask your doctor
- How quickly do I expect to see improvement with corticosteroids versus hypomethylating agents?
- What are the risks of long-term dependence on steroids for my specific case?
- How long should I expect to wait for a response from azacitidine or other hypomethylating agents?
- What signs indicate that my current treatment is working versus failing?
- Are there specific genetic mutations in my UBA1 gene that might predict how well I will respond to certain drugs?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.